Cure My Disease

Don't miss your cure!

 Log in / Sign up

Every-8-Week shot could simplify PNH treatment

NCT ID NCT06298955

Ongoing Disease control Sponsor: Omeros Corporation Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests the long-term safety of an experimental drug called OMS906 in people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. Participants receive OMS906 as an intravenous infusion every 8 weeks. The goal is to see if this dosing schedule is safe and tolerable over time, and to check if it helps maintain healthy hemoglobin levels and reduce the need for blood transfusions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
OMS906, an experimental drug given intravenously every 8 weeks
What this could lead to
If successful, this could provide a convenient, long-term treatment option for people with PNH, reducing the need for frequent infusions.
What could go wrong
This is an early-phase, open-label study with only 25 participants, so results may not apply to all patients. Long-term safety and effectiveness are still unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hemoglobinuria, Paroxysmal paroxysmal nocturnal hemoglobinuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

Contacts and locations

Locations

  • Omeros Investigational Site

    Aachen, Germany

  • Omeros Investigational Site

    Ulm, Germany

  • Omeros Investigational Site

    Lausanne, Switzerland

  • Omeros Investigational Site

    Kyiv, Ukraine

  • Omeros Investigational Site

    Leeds, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.